Skip to main content

Table 6 Prognostic factors of locoregional-recurrence free survival

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

Characteristics5-year LRRFSUnivariate
p-value
Multivariate
p-value
HR
(95% CI)
Age≤40 years (n = 38)94.7%0.1840.1870.397(0.010–1.564)
> 40 years (n = 46)84.3%
Tumor subtype1)Non-TNBC (n = 54)96.3%0.0090.0040.120(0.029–0.500)
TNBC (n = 30)75.8%
cT stages1–2 (n = 47)87.1%0.568
3–4 (n = 37)91.7%
cN stages2b or 3b (n = 63)88.7%0.915
3c (n = 21)90.2%
Malignant cells on FNABx of the IMN(−) or unknown (n = 44)89.8%0.961
(+) (n = 40)88.5%
Extent of IMNSingle ICS (n = 37)89.0%0.660
Multiple ICS (n = 47)89.2%
IMN long diameter< 1.0 cm (n = 42)92.5%0.2670.1290.365(0.099–1.330)
≥1.0 cm (n = 42)85.7%
Neoadjuvant chemotherapyPerformed (n = 66)92.3%0.1080.1670.242(0.034–1.626)
Not performed (n = 18)77.0%
Axillary surgeryALND (n = 74)88.9%0.889
SLNB (n = 10)90.0%
EQD2 of the IMN2)50.0–63.5 Gy (n = 35)85.5%0.544
63.6–70.4 Gy (n = 49)91.7%
  1. 1)TNBC was defined as tumors that were negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 on immunohistochemical staining of the breast tumor
  2. 2)Radiotherapy dose was calculated using the EQD2 assuming the α/β ratio of 3.5 Gy
  3. Abbreviations: LRRFS Locoregional-recurrence free survival, TNBC Triple-negative breast cancer; FNABx Fine needle aspiration biopsy, IMN Internal mammary node, ICS Intercostal space, ALND Axillary lymph node dissection; SLNB Sentinel lymph node biopsy, HR Hazard ratio, CI confidence interval, EQD2 Biologically equivalent dose in 2 Gy fractions